Clinical trial
Neoadjuvant Befotertinib Combined Bevacizumab or Platinum-based Double Chemotherapy for Resectable Locally-advanced EGFR Mutation-positive Non-Small Cell Lung Cancer
NCT06755684
Study timeline
Study start (actual)2024-11-07Date precision: day
Registry last updated2025-01-06
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
EGFRunresolved
Non-Small Cell Lung Cancerunresolved
Pemetrexedunresolved
Carboplatinunresolved
Bevacizumabunresolved
Antineoplastic Agentsunresolved
Tyrosine Kinase Inhibitorunresolved
Interventions
Sponsors & collaborators
Peng Zhanglead sponsor
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT06755684 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.